Brought to you by 
BMS gets Phase II heart attack candidate from KAI
26 May 2015
Executive Summary
Following a series of divestitures to rid itself of noncore assets, Bristol-Myers Squibb is back in pharma dealmaking, taking exclusive worldwide rights to protein kinase C (PKC) expert KAI Pharmaceuticals' lead cardiovascular candidate KAI9803.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS gets Phase II heart attack candidate from KAI
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice